Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liothyronine is a synthetic form of the thyroid hormone triiodothyronine (T3). It is indicated as a replacement or supplemental therapy for various etiologies of hypothyroidism, including primary, secondary, and tertiary hypothyroidism. It is also used as an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer for pituitary thyroid-stimulating hormone (TSH) suppression, and as a diagnostic agent in thyroid suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine exerts its effects by binding to thyroid hormone receptors, mediating thyroid hormone actions in peripheral tissues. It has a shorter half-life compared to levothyroxine (T4).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on liothyronine.